Protein Kinase G I and Heart Failure: Shifting Focus from Vascular Unloading to Direct Myocardial Antiremodeling Effects

Overview

Journal Circ Heart Fail

Specialty Cardiology & Vascular Diseases

Date 2013 Nov 21

PMID 24255056

Citations 20

Authors

Qingwu Kong

Robert M Blanton

Affiliations

Soon will be listed here.

Citing Articles

Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study.

Zhan Y, Li L, Zhou J, Ma Y, Guan X, Wang S BMC Cardiovasc Disord. 2025; 25(1):83.

PMID: 39910422 PMC: 11796121. DOI: 10.1186/s12872-025-04477-2.

Cellular signalling of melatonin and its role in metabolic disorders.

Tripathy S, Bhattamisra S Mol Biol Rep. 2025; 52(1):193.

PMID: 39903334 DOI: 10.1007/s11033-025-10306-8.

Sacubitril/valsartan improves diastolic left ventricular stiffness with increased titin phosphorylation via cGMP-PKG activation in diabetic mice.

Furukawa N, Matsui H, Sunaga H, Nagata K, Hirayama M, Obinata H Sci Rep. 2024; 14(1):25081.

PMID: 39443532 PMC: 11499646. DOI: 10.1038/s41598-024-75757-8.

The impact of phosphodiesterase-5 inhibition or angiotensin-converting enzyme inhibition on right and left ventricular remodeling in heart failure due to chronic volume overload.

Tykvartova T, Miklovic M, Kotrc M, Skaroupkova P, Kazdova L, Trnovska J Pharmacol Res Perspect. 2024; 12(1):e1172.

PMID: 38284173 PMC: 10823410. DOI: 10.1002/prp2.1172.

Falling corin and ANP activity levels accelerate development of heart failure and cardiac fibrosis.

Gladysheva I, Sullivan R, Reed G Front Cardiovasc Med. 2023; 10:1120487.

PMID: 37388639 PMC: 10309071. DOI: 10.3389/fcvm.2023.1120487.

References

Khairallah M, Khairallah R, Young M, Allen B, Gillis M, Danialou G . Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci U S A. 2008; 105(19):7028-33. PMC: 2383977. DOI: 10.1073/pnas.0710595105. View

Solomon S, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E . The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012; 380(9851):1387-95. DOI: 10.1016/S0140-6736(12)61227-6. View

Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi M . The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004; 44(12):2339-48. DOI: 10.1016/j.jacc.2004.09.041. View

Fisher P, Salloum F, Das A, Hyder H, Kukreja R . Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation. 2005; 111(13):1601-10. DOI: 10.1161/01.CIR.0000160359.49478.C2. View

Wollert K, Fiedler B, Gambaryan S, Smolenski A, Heineke J, Butt E . Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension. 2002; 39(1):87-92. DOI: 10.1161/hy1201.097292. View

Mitrovic V, Seferovic P, Simeunovic D, Ristic A, Miric M, Moiseyev V . Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006; 27(23):2823-32. DOI: 10.1093/eurheartj/ehl337. View

Tang K, Wang G, Lu P, Karas R, Aronovitz M, Heximer S . Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med. 2003; 9(12):1506-12. DOI: 10.1038/nm958. View

Kato M, Blanton R, Wang G, Judson T, Abe Y, Myoishi M . Direct binding and regulation of RhoA protein by cyclic GMP-dependent protein kinase Iα. J Biol Chem. 2012; 287(49):41342-51. PMC: 3510832. DOI: 10.1074/jbc.M112.421040. View

Kishimoto I, Rossi K, Garbers D . A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci U S A. 2001; 98(5):2703-6. PMC: 30202. DOI: 10.1073/pnas.051625598. View

10.

Fiedler B, Lohmann S, Smolenski A, Linnemuller S, Pieske B, Schroder F . Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A. 2002; 99(17):11363-8. PMC: 123262. DOI: 10.1073/pnas.162100799. View

11.

Franciosa J, Cohn J . Hemodynamic responsiveness to short- and long-acting vasodilators in left ventricular failure. Am J Med. 1978; 65(1):126-33. DOI: 10.1016/0002-9343(78)90701-5. View

12.

Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C . Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation. 2009; 119(3):408-16. PMC: 3791110. DOI: 10.1161/CIRCULATIONAHA.108.822072. View

13.

Franciosa J, Nordstrom L, Cohn J . Nitrate therapy for congestive heart failure. JAMA. 1978; 240(5):443-6. View

14.

Guazzi M, Vicenzi M, Arena R, Guazzi M . Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011; 124(2):164-74. DOI: 10.1161/CIRCULATIONAHA.110.983866. View

15.

Yuasa K, Michibata H, Omori K, Yanaka N . A novel interaction of cGMP-dependent protein kinase I with troponin T. J Biol Chem. 1999; 274(52):37429-34. DOI: 10.1074/jbc.274.52.37429. View

16.

Ichinose F, Bloch K, Wu J, Hataishi R, Aretz H, Picard M . Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am J Physiol Heart Circ Physiol. 2003; 286(3):H1070-5. DOI: 10.1152/ajpheart.00940.2003. View

17.

Redfield M, Chen H, Borlaug B, Semigran M, Lee K, Lewis G . Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309(12):1268-77. PMC: 3835156. DOI: 10.1001/jama.2013.2024. View

18.

Mullens W, Abrahams Z, Francis G, Skouri H, Starling R, Young J . Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008; 52(3):200-7. DOI: 10.1016/j.jacc.2008.02.083. View

19.

Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi M . Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007; 50(22):2136-44. DOI: 10.1016/j.jacc.2007.07.078. View

20.

Yusuf S, Pitt B, Davis C, Hood W, Cohn J . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325(5):293-302. DOI: 10.1056/NEJM199108013250501. View